TY - JOUR
T1 - Harmonisation of D-dimer
T2 - A call for action
AU - Longstaff, Colin
AU - Adcock, Dorothy
AU - Olson, John D
AU - Jennings, Ian
AU - Kitchen, Steve
AU - Mutch, Nicola
AU - Meijer, Piet
AU - Favaloro, Emmanuel J
AU - Lippi, Giuseppe
AU - Thachil, Jecko
PY - 2016/1/1
Y1 - 2016/1/1
N2 - D-dimer is a stable, terminal product of fibrin degradation in plasma. In the 1970s, Gaffney and colleagues introduced the concept of D-dimer measurement as a biomarker of coagulation activation and fibrin formation [ [1] ]. Since then, D-dimer has been used in the diagnostic process of various conditions, including the exclusion of venous thromboembolism, diagnostic scores for disseminated intravascular coagulation (DIC), thromboembolic risk in patients with atrial fibrillation, to help identify the cause of acute-onset chest pain (e.g., aortic aneurysm) and more recently, for the assessment of an individual's risk for venous thromboembolism recurrence after a first event. Although the D-dimer assay is a significant advancement to the pre-existing measurement of fibrin and fibrinogen degradation products [ [2] ], which were hugely influenced by a number of artefacts, several issues exist with its routine use that compromise its utility. This communication, from the Fibrinolysis and DIC Standardisation Subcommittees of the ISTH and other concerned colleagues is a call for further efforts to harmonise D-dimer measurement.
AB - D-dimer is a stable, terminal product of fibrin degradation in plasma. In the 1970s, Gaffney and colleagues introduced the concept of D-dimer measurement as a biomarker of coagulation activation and fibrin formation [ [1] ]. Since then, D-dimer has been used in the diagnostic process of various conditions, including the exclusion of venous thromboembolism, diagnostic scores for disseminated intravascular coagulation (DIC), thromboembolic risk in patients with atrial fibrillation, to help identify the cause of acute-onset chest pain (e.g., aortic aneurysm) and more recently, for the assessment of an individual's risk for venous thromboembolism recurrence after a first event. Although the D-dimer assay is a significant advancement to the pre-existing measurement of fibrin and fibrinogen degradation products [ [2] ], which were hugely influenced by a number of artefacts, several issues exist with its routine use that compromise its utility. This communication, from the Fibrinolysis and DIC Standardisation Subcommittees of the ISTH and other concerned colleagues is a call for further efforts to harmonise D-dimer measurement.
KW - Antifibrinolytic Agents
KW - Blood Chemical Analysis/methods
KW - Fibrin Fibrinogen Degradation Products/analysis
KW - Humans
KW - Immunoassay/methods
KW - Practice Guidelines as Topic
U2 - 10.1016/j.thromres.2015.11.031
DO - 10.1016/j.thromres.2015.11.031
M3 - Letter
C2 - 26620264
SN - 0049-3848
VL - 137
SP - 219
EP - 220
JO - Thrombosis Research
JF - Thrombosis Research
ER -